SLNO: the balance sheet

MyFinsight

For the quarter ending 2025-09-30, SLNO has $599,895K in assets. $105,090K in debts. $246,662K in cash and cash equivalents.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Balance Sheets	2025-09-30	2025-06-30
Cash and cash equivalents	246,662	76,497
Marketable securities	252,272	210,344
Accounts receivable, net	25,506	24,624
Inventory, net	6,674	2,355
Prepaid expenses and other current assets	3,739	2,969
Total current assets	534,853	316,789
Property and equipment, net	150	166
Operating lease right-of-use assets	2,314	2,434
Intangible assets, net	5,347	5,832
Long-term marketable securities	57,148	7,002
Other long-term assets	83	83
Total assets	599,895	332,306

Accrued interest payable	-	409
Accounts payable	8,145	6,216
Accrued compensation	7,248	6,267
Operating lease liabilities	697	676
Accrued clinical trial site costs	-	1,863
Other current liabilities	17,163	5,512
Total current liabilities	33,253	20,943
Contingent liability for essentialis purchase price	19,473	18,859
Long-term debt, net	49,854	49,845
Long-term lease liabilities	2,112	2,248
Other long-term liabilities	398	271
Total liabilities	105,090	92,166
Common stock, 0.001 par value, 100,000,000 shares authorized, 53,703,675 and 45,703,811 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively	54	50
Additional paid-in-capital	969,119	740,746
Accumulated other comprehensive income	360	85
Accumulated deficit	-474,728	-500,741
Total stockholders equity	494,805	240,140
Total liabilities and stockholders equity	599,895	332,306